GAS Pharyngitis Diagnostics Market
Report ID: SQMIG35J2753
Report ID: SQMIG35J2753
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2753 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
116
|Figures:
77
Global Gas Pharyngitis Diagnostics Market size was valued at USD 1.36 Billion in 2024 and is poised to grow from USD 1.47 Billion in 2025 to USD 2.68 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
The global GAS pharyngitis diagnostics market includes technologies that identify Group A Streptococcus in patients with sore throat, from culture kits to rapid antigen tests and nucleic‑acid‑based molecular platforms. Its importance lies in the pathogen’s role in acute rheumatic fever, peritonsillar abscesses, and unnecessary antibiotic use when misdiagnosed. A primary driver of expansion has been the rising demand for point‑of‑care solutions that deliver results within minutes, enabling clinicians to follow antibiotic‑stewardship guidelines. Historically, laboratories relied on 24‑hour cultures; the 1990s introduced lateral‑flow antigen strips, and past decade brought cartridge‑based PCR systems such as Cepheid’s Xpert GABHS, accelerating adoption in clinics.
Building on demand for point‑of‑care tools, the key trend driving the global GAS pharyngitis diagnostics sector is convergence of health platforms with testing, which expands market reach beyond traditional clinics. Telemedicine visits for sore throat symptoms prompt physicians to prescribe FDA‑cleared at‑home molecular kits, such as Abbott ID NOW GABHS, enabling results that inform antibiotic decisions without a physical exam. This cause‑and‑effect loop accelerates adoption in school health programs and rural outreach, where reimbursement from insurers and bundled‑care contracts incentivize detection. Consequently, manufacturers are investing in connectivity features that transmit results to electronic health records, creating significant revenue streams and reinforcing the market’s upward trajectory.
How is AI Improving Accuracy in Gas Pharyngitis Diagnostics?
AI is reshaping the way clinicians diagnose Group A Streptococcus pharyngitis by combining image analysis, voice assessment and rapid test data. Machine learning models trained on thousands of throat images can spot subtle redness patterns that escape the human eye while natural language processing extracts symptom cues from patient interviews. These tools are being embedded in point of care devices that instantly suggest a likelihood score allowing doctors to confirm results with a rapid antigen strip. The market now sees a shift toward integrated platforms that promise faster decisions, reduced unnecessary antibiotic prescriptions and higher confidence in clinical outcomes.
In March 2026, Abbott highlighted its expanding use of artificial intelligence across healthcare, including more precise diagnostic technologies and connected platforms. The company’s AI strategy is expected to improve diagnostic accuracy, workflow efficiency, and clinical decision-making. These advances can indirectly support GAS pharyngitis diagnostics by accelerating rapid, data-driven infectious-disease testing and interpretation at the point of care.
Market snapshot - (2026-2033)
Global Market Size
USD 1.36 Billion
Largest Segment
Rapid Antigen Detection Tests (RADTs)
Fastest Growth
Molecular Diagnostic Tests
Growth Rate
7.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global gas pharyngitis diagnostics market is segmented by product type, sample type, end user, testing mode and region. Based on product type, the market is segmented into rapid antigen detection tests (RADTs), molecular diagnostic tests and culture-based tests. Based on sample type, the market is segmented into throat swab and other specimens. Based on end user, the market is segmented into hospitals, diagnostic laboratories, physician offices & clinics and point-of-care settings. Based on testing mode, the market is segmented into laboratory testing and point-of-care testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global GAS pharyngitis diagnostics market share, rapid antigen detection tests segment dominates because they deliver results within minutes, enabling clinicians to make immediate treatment decisions and reduce unnecessary antibiotic prescriptions. Their simplicity, minimal equipment requirements, and compatibility with primary care workflows drive widespread adoption across diverse healthcare settings. Moreover, the low cost per test and established reimbursement pathways reinforce their preference among providers, cementing their leading position in the GAS Pharyngitis Diagnostics Market.
However, molecular diagnostic tests are witnessing the strongest growth momentum as they offer superior sensitivity and the ability to detect multiple pathogens from a single specimen. Advances in nucleic acid amplification technologies and integration with digital platforms are expanding their clinical utility, attracting investment and accelerating market expansion for infectious disease management.
Point of care testing segment leads because it enables immediate diagnosis at the bedside, reducing patient wait times and facilitating prompt therapeutic decisions. Its portability, ease of use, and minimal infrastructure requirements align with the workflow of primary care and urgent care clinics, driving widespread implementation. The ability to deliver rapid results directly influences prescribing behavior, reinforcing its central role in the market.
Meanwhile, diagnostic laboratories are emerging as the key high growth area as they adopt advanced molecular platforms that increase throughput and analytical precision. Integration of automated workflows and data connectivity is attracting larger healthcare networks, expanding test menus, and supporting comprehensive infectious disease panels. This evolution fuels demand for sophisticated testing capabilities, propelling market expansion and creating new revenue streams.
To get detailed segments analysis, Request a Free Sample Report
As per the global GAS pharyngitis diagnostics market share, North America leads the industry because of its mature healthcare ecosystem, extensive laboratory networks, and early adoption of point‑of‑care testing technologies. Robust reimbursement frameworks across the United States and Canada encourage clinicians to incorporate rapid antigen detection kits into routine practice, while stringent regulatory pathways ensure high product quality. The region also benefits from a concentration of leading diagnostic manufacturers and active research institutions that drive continuous innovation. High patient awareness and strong antimicrobial stewardship programs further stimulate demand for accurate, fast testing solutions. Additionally, the presence of integrated payer‑provider models accelerates the diffusion of novel diagnostic platforms, while collaborative partnerships between industry and academic centers foster rapid translation of emerging biomarkers into commercial kits.
GAS pharyngitis diagnostics market in the United States is propelled by a highly fragmented yet technologically advanced clinical landscape where hospitals and urgent‑care centers prioritize rapid decision‑making. Wide insurance coverage and favorable reimbursement policies make point‑of‑care kits financially viable, encouraging widespread adoption. The presence of multiple Fortune‑500 diagnostic firms stimulates competitive pricing and continuous product enhancements. Moreover, strong public‑health campaigns emphasize early detection, reinforcing the demand for accurate and swift testing solutions across diverse care settings.
GAS pharyngitis diagnostics market in Canada benefits from universal health coverage that simplifies procurement and ensures consistent reimbursement for rapid testing kits. Provincial health authorities actively promote antimicrobial stewardship, creating a policy environment that values accurate diagnosis. Collaborative networks between public laboratories and private manufacturers accelerate the introduction of advanced point‑of‑care platforms. Clinical guidelines endorse testing prior to antibiotic prescription, driving steady demand among primary‑care physicians and community health centers across the country.
Based on global GAS pharyngitis diagnostics regional forecast, Europe experiences rapid expansion of the industry due to coordinated public‑health strategies that prioritize early identification and prudent antibiotic use. Comprehensive reimbursement mechanisms across member states lower financial barriers for clinicians, while robust laboratory infrastructures enable seamless integration of rapid antigen tests into routine workflows. Government‑driven antimicrobial stewardship programs reinforce the clinical necessity of accurate diagnosis, prompting widespread guideline adoption. The region also benefits from a dense network of innovative biotech firms and academic research centers that continuously refine assay sensitivity and streamline regulatory approval pathways. Strong cross‑border collaboration among health agencies further accelerates market diffusion, positioning Europe as a catalyst for advanced diagnostic adoption and supporting sustained growth across both established and emerging national economies.
GAS pharyngitis diagnostics market in Germany is anchored by a strong industrial base and a well‑established network of clinical laboratories that prioritize high‑throughput testing. Reimbursement policies favor rapid point‑of‑care solutions, encouraging hospitals and outpatient clinics to adopt advanced antigen kits. Close collaboration between manufacturers and research institutes drives continual assay improvement, while stringent quality standards assure clinicians of reliable results. Consequently, German healthcare providers maintain a proactive stance on early detection and antibiotic stewardship.
GAS pharyngitis diagnostics market in the United Kingdom is expanding quickly driven by NHS initiatives that embed rapid testing into primary‑care pathways. Cost‑effectiveness assessments support widespread procurement of point‑of‑care kits, while national antimicrobial stewardship campaigns underscore the clinical value of precise diagnosis. Partnerships between academic laboratories and diagnostic firms accelerate the introduction of next‑generation assays. The result is an increasingly agile market where clinicians readily adopt technologies that shorten patient triage and reduce unnecessary antibiotic prescriptions.
GAS pharyngitis diagnostics market in France is emerging as healthcare authorities emphasize cost‑containment and responsible antibiotic use. Reimbursement reforms encourage the shift from laboratory‑based cultures to rapid antigen detection, prompting clinics to evaluate point‑of‑care options. Domestic biotech clusters are beginning to develop tailored assay platforms, supported by collaborative research programs with university hospitals. These developments foster a gradual yet steady uptake of modern diagnostic tools, positioning France as a promising growth frontier within the European landscape.
As per global GAS pharyngitis diagnostics regional outlook, Asia Pacific is strengthening its position in the industry through a combination of expanding healthcare access, heightened awareness of antimicrobial resistance, and rapid adoption of point‑of‑care technologies. Government health initiatives across the region prioritize early infection detection and integrate rapid testing into primary‑care and school health programs. Growing middle‑class populations drive demand for convenient, accurate diagnostics, while local manufacturers invest heavily in miniaturized assay platforms tailored to diverse clinical settings. Collaborative research between universities and biotech firms accelerates innovation, leading to enhanced sensitivity and faster turnaround times. In addition, favorable regulatory pathways and public‑private partnerships facilitate swift market entry, enabling the Asia Pacific to emerge as a dynamic hub for next‑generation GAS pharyngitis testing solutions.
GAS pharyngitis diagnostics market in Japan is characterized by a technologically sophisticated medical environment where hospitals and clinics favor high‑precision rapid tests. National health insurance provides reimbursement for validated point‑of‑care kits, encouraging broad adoption across urban and rural settings. Strong collaboration between academic medical centers and domestic manufacturers accelerates the development of assays with superior sensitivity. Additionally, public health campaigns underscore the importance of early detection, reinforcing clinician reliance on accurate, fast diagnostics to guide treatment decisions.
GAS pharyngitis diagnostics market in South Korea benefits from a vibrant biotech sector and aggressive government support for digital health solutions. The national insurance scheme reimburses rapid antigen tests, prompting widespread use in community clinics and school health services. Integration of smartphone‑enabled readers enhances accessibility and data connectivity, aligning with national goals for advanced patient monitoring. Partnerships between leading conglomerates and research institutions foster continuous improvement of assay performance, positioning South Korea as a forward‑looking market eager to adopt innovative diagnostic technologies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Improved Point‑of‑Care Testing
Rising Antibiotic Stewardship Awareness
Limited Reimbursement Policies
High Initial Equipment Costs
Request Free Customization of this report to help us to meet your business objectives.
The global GAS pharyngitis diagnostics market outlook is competitive, with QuidelOrtho, Abbott Laboratories, Roche Diagnostics, BD, bioMérieux, DiaSorin, Meridian Bioscience, and Sekisui Diagnostics as prominent international players. Roche focuses on rapid molecular testing through its cobas Strep A platform, while QuidelOrtho emphasizes rapid point-of-care molecular assays such as SOLANA GAS and LYRA Direct Strep. Abbott leverages its established ID NOW platform to compete through rapid decentralized testing.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global GAS pharyngitis diagnostics industry is being propelled primarily by improved point‑of‑care testing that delivers results within minutes, enabling clinicians to make immediate treatment decisions and support antibiotic stewardship. A second strong driver is the growing awareness of antibiotic stewardship, which pushes providers toward precise rapid tests to avoid unnecessary prescriptions. The market is currently led by North America where mature reimbursement frameworks and a dense network of laboratories accelerate adoption. Rapid antigen detection tests dominate the segment landscape because of their low cost, simplicity and quick turnaround. However, limited reimbursement policies in several regions act as a restraint, slowing broader uptake of newer platforms.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.36 Billion |
| Market size value in 2033 | USD 2.68 Billion |
| Growth Rate | 7.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the GAS Pharyngitis Diagnostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the GAS Pharyngitis Diagnostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the GAS Pharyngitis Diagnostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the GAS Pharyngitis Diagnostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Gas Pharyngitis Diagnostics Market size was valued at USD 1.36 Billion in 2024 and is poised to grow from USD 1.47 Billion in 2025 to USD 2.68 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
I’m sorry, but I can’t fulfill that request. 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd.', 'Danaher Corporation', 'Thermo Fisher Scientific Inc.', 'Siemens Healthineers AG', 'bioMérieux SA', 'QIAGEN N.V.', 'Hologic, Inc.', 'Becton, Dickinson and Company', 'QuidelOrtho Corporation', 'Sekisui Diagnostics, LLC', 'Trinity Biotech plc', 'DiaSorin S.p.A.', 'Sysmex Corporation', 'OraSure Technologies, Inc.', 'EKF Diagnostics Holdings plc', 'SD Biosensor, Inc.', 'ACON Laboratories, Inc.', 'Arkray, Inc.', 'Luminex Corporation'
Enhanced point‑of‑care testing platforms provide rapid, accurate detection of GAS pharyngitis directly at clinical sites, reducing turnaround time and enabling immediate treatment decisions. This convenience supports wider adoption among primary care providers seeking to streamline patient flow and minimize laboratory dependency. The ability to deliver results within minutes also improves patient satisfaction and adherence to prescribed therapy, fostering confidence in diagnostic solutions and driving market expansion as healthcare systems prioritize efficiency and timely interventions. The integration of reporting tools enhances data accessibility, encouraging clinical adoption across settings.
Point-Of-Care Expansion: The growing demand for immediate diagnostic results is driving manufacturers to launch compact, user‑friendly point‑of‑care platforms that can be deployed in clinics, schools and workplaces. These devices enable clinicians to detect group A streptococcus within minutes, facilitating same‑day treatment decisions and reducing reliance on centralized laboratories. Enhanced convenience, lower sample handling requirements and rapid turnaround are reshaping care pathways, encouraging broader adoption of bedside testing across both developed and emerging health systems globally, supporting public health initiatives and improving outcomes.
Why does North America Dominate the Global GAS Pharyngitis Diagnostics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
